| Symbol | GLMD |
|---|---|
| Name | GALMED PHARMACEUTICALS LTD. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | C/O MEITAR LAW OFFICES,ABBA HILLEL SILVER RD., RAMAT GAN, 5250608, Israel |
| Telephone | +972 36938448 |
| Fax | — |
| — | |
| Website | https://www.galmedpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001595353 |
| Description | Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis. Additional info from NASDAQ: |
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics
Read moreGalmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers
Read moreGalmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers
Read moreGalmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
Read moreGalmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
Read moreNew Form EFFECT - Galmed Pharmaceuticals Ltd. <b>Filed:</b> 2026-04-01 <b>AccNo:</b> 9999999995-26-001038 <b>Size:</b> 1 KB
Read moreGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
Read moreGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07251712 | Single and Multiple Dose Pharmacokinetics (PK) of Aramchol From an Aramchol Meg… | Phase1 | Healthy | Recruiting | 2025-12-25 | 2026-05-15 | ClinicalTrials.gov |
| NCT06095986 | A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine… | Phase2 | Primary Sclerosing Cholangitis | Withdrawn | 2025-06-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT06502561 | Comparing The PK Of Aramchol Meglumine Granules To Aramchol Free Acid Tablets | Phase1 | Healthy | Active_Not_Recruiting | 2025-02-15 | 2025-12-01 | ClinicalTrials.gov |
| NCT05857215 | A First-in-Human Study of Single and Multiple Doses of Amilo-5MER in Healthy Su… | Phase1 | Inflammatory Disease | Completed | 2021-03-05 | 2021-07-01 | ClinicalTrials.gov |
| NCT05874336 | An Open-Label, Two-Part Study Designed to Assess the Absolute Bioavailability a… | Phase1 | NASH | Completed | 2020-06-17 | 2020-08-11 | ClinicalTrials.gov |
| NCT03774173 | Comparison of Aramchol Concentrations With Once or Twice Daily Dosing | Phase1 | Healthy | Completed | 2018-12-08 | 2019-03-05 | ClinicalTrials.gov |
| NCT03760848 | Study of Potential for Drug Interactions Mediated by CYP3A4 Inhibition With Ara… | Phase1 | Healthy | Completed | 2018-11-12 | 2019-02-02 | ClinicalTrials.gov |
| NCT02803996 | Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol Administer… | Phase1 | Healthy Volunteers | Completed | 2016-05-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02279524 | A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Vers… | Phase2 | Fatty Liver | Completed | 2015-04-29 | 2018-05-22 | ClinicalTrials.gov |
| NCT02325492 | Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of … | Phase2 | Gallstones | Terminated | 2014-10-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02374437 | Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol and Food E… | Phase1 | Healthy Volunteers | Completed | 2014-04-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01362361 | TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxalipla… | Phase2 | Colorectal Cancer | Completed | 2011-06-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01094158 | Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohe… | Phase2 | Non-Alcoholic Fatty Liver Disease | Completed | 2010-11-01 | 2012-01-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Aramchol | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03774173 |
| Placebo | Other | Phase PHASE2 | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT01094158 |
| Aramchol | Other | Phase PHASE2 | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT01094158 |
| Placebo | Other | Phase PHASE2 | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT01094158 |
| Aramchol | Other | Phase PHASE2 | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT01094158 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02374437 |
| Aramchol | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02374437 |
| Ultrasound | Other | Phase PHASE2 | Gallstones | TERMINATED | NCT02325492 |
| Placebo | Other | Phase PHASE2 | Gallstones | TERMINATED | NCT02325492 |
| Aramchol | Other | Phase PHASE2 | Gallstones | TERMINATED | NCT02325492 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02803996 |
| Aramchol | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02803996 |
| Atorvastatin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03760848 |
| Midazolam | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03760848 |
| Aramchol | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03760848 |
| mFOLFOX6+placebo | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT01362361 |
| mFOLFOX6 + BIBF 1120 | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT01362361 |
| Aramchol | Other | Phase PHASE2 | Fatty Liver | COMPLETED | NCT02279524 |
| amilo-5MER | Other | Phase PHASE1 | Inflammatory Disease | COMPLETED | NCT05857215 |
| Aramchol | Other | Phase PHASE1 | NASH | COMPLETED | NCT05874336 |
| Aramchol meglumine | Other | Phase PHASE2 | Primary Sclerosing Cholangitis | WITHDRAWN | NCT06095986 |
| Aramchol free acid | Other | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT06502561 |
| Aramchol meglumine | Other | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT06502561 |
| Aramchol | Other | Phase PHASE1 | Healthy | RECRUITING | NCT07251712 |
| Aramchol free acid | DRUG | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT06502561 |
| Aramchol meglumine | DRUG | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT06502561 |
| amilo-5MER | DRUG | Phase PHASE1 | Inflammatory Disease | COMPLETED | NCT05857215 |
| Atorvastatin | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT03760848 |
| Midazolam | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT03760848 |
| Ultrasound | DEVICE | Phase PHASE2 | Gallstones | TERMINATED | NCT02325492 |
| Placebo | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02803996 |
| Aramchol | DRUG | Phase PHASE1 | Healthy | RECRUITING | NCT07251712 |